ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval

Nicole DeFeudis

Editor

When ImmunoGen’s lead antibody-drug conjugate flunked a Phase III study in ovarian cancer a couple years ago, the company clung to hope that it would …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval

Nicole DeFeudis

Editor

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Eli Lilly reports first Phase 3 data for oral GLP-1, posting a win in diabetes

Sarepta loses CMO to RNA editing upstart; Another wave of personnel moves at Dyne

Netherlands pours $1.5B into biotech in pursuit of global leadership ambitions

Sanofi to pay $125M upfront for two immunology drugs from little-known biotech

Exclusive: BigHat inks Lilly deal for AI-boosted antibodies, extends Series B

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

Im­muno­Gen touts a PhI­II come­back in ovar­i­an can­cer, eye­ing a 2022 ac­cel­er­at­ed ap­proval

Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval